EGFR and non-small cell lung carcinoma: These findings suggest that third‐generation EGFR‐TKIs might have efficacy similar to pemetrexed chemotherapy in T790M‐negative NSCLC patients and could be a potential treatment option for T790M‐negative patients who have previously received first‐ or second‐generation EGFR‐TKIs treatment.